Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.

ABSTRACT:

Background

Everolimus is a mTOR inhibitor used for the treatment of different solid malignancies. Many patients treated with the registered fixed 10 mg dose once daily are in need of dose interruptions, reductions or treatment discontinuation due to severe adverse events. This study determined the correlation between systemic everolimus exposure and toxicity. Additionally, the effect of different covariates on everolimus pharmacokinetics (PK) was explored.

Methods

Forty-two patients with advanced thyroid carcinoma were treated with 10 mg everolimus once daily. Serial pharmacokinetic sampling was performed on days 1 and 15. Subsequently, a population PK model was developed using NONMEM to estimate individual PK values used for analysis of an exposure-toxicity relationship. Fu

SUBMITTER: de Wit D 

PROVIDER: S-EPMC4921118 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature